Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

1 Issue per year


IMPACT FACTOR 2016 (Open Medicine): 0.294
IMPACT FACTOR 2016 (Central European Journal of Medicine): 0.116

CiteScore 2016: 0.28

SCImago Journal Rank (SJR) 2015: 0.140
Source Normalized Impact per Paper (SNIP) 2015: 0.154

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 8, Issue 6 (Dec 2013)

Issues

Predictors of treatment response in patients with hepatitis C 1b genotype

Vadim Brjalin
  • Department of Internal Medicine, West-Tallinn Central Hospital, Paldiski Road 68, 10617, Tallinn, Estonia
  • Department of Internal Medicine, University of Tartu, L. Puusepa 6, 51014, Tartu, Estonia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Riina Salupere / Tatjana Tallo
  • Department of Virology, National Institute for Health Development, Hiiu 42, 11619, Tallinn, Estonia
  • Department of Diagnostics and Vaccine, Unit for Molecular Typing, Swedish Institute for Communicable Disease Control, Nobels väg 18, 17182, Solna, Sweden
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Tatiana Kuznetsova / Ljudmilla Priimägi / Valentina Tefanova
Published Online: 2013-12-06 | DOI: https://doi.org/10.2478/s11536-013-0221-2
  • [1] World Health Organization Viral Cancers: Hepatitis C virus. Accessed 2010 May 28. Available from: URL: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html#disease%20burden Google Scholar

  • [2] Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., et al., Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes, Hepatology, 2005, 42(4), 962–973 http://dx.doi.org/10.1002/hep.20819CrossrefGoogle Scholar

  • [3] Lavanchy D., Evolving epidemiology of hepatitis C virus, Clin. Microbiol. Infect., 2011, 17(2), 107–115 http://dx.doi.org/10.1111/j.1469-0691.2010.03432.xCrossrefWeb of ScienceGoogle Scholar

  • [4] Esteban J.I., Sauleda S., Quer J., The changing epidemiology of hepatitis C virus infection in Europe, J. Hepatol., 2008, 48, 148–162 http://dx.doi.org/10.1016/j.jhep.2007.07.033CrossrefGoogle Scholar

  • [5] Tallo T., Norder H., Tefanova V., Krispin T., Schmidt J., Ilmoja M., et al., Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominanting subtype with time, J. Med. Virol., 2007, 79(4), 374–382 http://dx.doi.org/10.1002/jmv.20828Web of ScienceCrossrefGoogle Scholar

  • [6] Zusinaite E., Krispin T., Raukas E., Kiiver K., Salupere R., Ott K., et al., Hepatitis C virus genotypes in Estonia, APMIS, 2000, 108(11), 739–746 http://dx.doi.org/10.1034/j.1600-0463.2000.d01-23.xCrossrefGoogle Scholar

  • [7] Tefanova V., Tallo T., Kutsar K., Priimgi L., Urgent action needed to stop spread of hepatitis B and C in Estonian drug users, Euro Surveill., 2006, 11, E060126.3 Google Scholar

  • [8] Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B., Diagnosis, management, and treatment of hepatitis C: an update, Hepatology, 2009, 49, 1335–1374 http://dx.doi.org/10.1002/hep.22759CrossrefGoogle Scholar

  • [9] EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J. Hepatol., 2011, 55, 245–264 Google Scholar

  • [10] Shiffman M.L., Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders, Curr. Gastroenterol. Rep., 2006, 8(1), 46–52 http://dx.doi.org/10.1007/s11894-006-0063-zCrossrefGoogle Scholar

  • [11] Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet, 2001, 358, 958–965 http://dx.doi.org/10.1016/S0140-6736(01)06102-5CrossrefGoogle Scholar

  • [12] Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L. Jr, et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N. Engl. J. Med., 2002, 347, 975–982 http://dx.doi.org/10.1056/NEJMoa020047Google Scholar

  • [13] Hadziyannis S.J., Sette H.Jr., Morgan T.R., Balan V., Diago M., Marcellin P., et al., Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann. Intern. Med., 2004, 140(5), 346–355 http://dx.doi.org/10.7326/0003-4819-140-5-200403020-00010Google Scholar

  • [14] McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., et al., Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection, N. Engl. J. Med., 2009, 361(6), 580–593 http://dx.doi.org/10.1056/NEJMoa0808010Web of ScienceGoogle Scholar

  • [15] Ferenci P., Optimal treatment duration for patients with HCV genotype 1 infection, J. Viral. Hepat., 2012, 19(Suppl 1), 7–13 http://dx.doi.org/10.1111/j.1365-2893.2011.01522.xCrossrefGoogle Scholar

  • [16] Yu J.W., Sun L.J., Zhao Y.H., Kang P., Yan B.Z., Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment, Int. J. Infect. Dis., 2011, 15(11), 740–746 http://dx.doi.org/10.1016/j.ijid.2011.05.018CrossrefGoogle Scholar

  • [17] Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., et al., Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy, Hepatology, 2003, 37(3), 600–609 http://dx.doi.org/10.1053/jhep.2003.50106CrossrefGoogle Scholar

  • [18] Zeuzem S., Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann. Intern. Med., 2004, 140(5), 370–381 Google Scholar

  • [19] Foster G.R., Fried M.W., Hadziyannis S.J., Messinger D., Freivogel K., Weiland O., Predicting of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin, Scand. J. Gastroenterol., 2007, 42(2), 247–255 http://dx.doi.org/10.1080/00365520600955526Web of ScienceCrossrefGoogle Scholar

  • [20] Hoofnagle J.H., Wahed A.S., Brown R.S.Jr., Howell C.D., Belle S.H., Virahep-C Study Group, Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection, J. Infect. Dis., 2009, 199(8), 1112–1120 http://dx.doi.org/10.1086/597384CrossrefGoogle Scholar

  • [21] Saludes V., Bracho M.A., Valero O., Ardevol M., Planas R., Gonzalez-Candelas F., et al., Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors, PloS One, 2010, 5(11), e14132 http://dx.doi.org/10.1371/journal.pone.0014132CrossrefGoogle Scholar

  • [22] Puig-Basagoiti F., Forns X., Furcić I., Ampurdanés S., Giménez-Barcons M., Franco S., et al., Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C, J. Gen. Virol., 2005, 86(Pt 4), 1067–1075 http://dx.doi.org/10.1099/vir.0.80526-0CrossrefGoogle Scholar

  • [23] Villela-Nogueira C.A., Perez R.M., de Segadas Soares J.A., Coelho H.S., Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin, J. Clin. Gastroenterol., 2005, 39(8), 728–730 http://dx.doi.org/10.1097/01.mcg.0000174025.19214.32CrossrefGoogle Scholar

  • [24] Jacobson I.M., Brown R.S. Jr., Freilich B., Afdhal N., Kwo P.Y., Santoro J., et al., Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial, Hepatology, 2007, 46(4), 971–981 http://dx.doi.org/10.1002/hep.21932CrossrefGoogle Scholar

  • [25] Poordad F., Reddy K.R., Martin P., Rapid virologic response: a new milestone in the management of chronic hepatitis C, Clin. Infect. Dis., 2008, 46(1), 78–84 http://dx.doi.org/10.1086/523585Web of ScienceCrossrefGoogle Scholar

  • [26] Fried M.W., Hadziyannis S.J., Shiffman M.L., Messinger D., Zeuzem S., Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection, J. Hepatol., 2011, 55(1), 69–75 http://dx.doi.org/10.1016/j.jhep.2010.10.032CrossrefWeb of ScienceGoogle Scholar

  • [27] Clark P.J., Thompson A.J., McHutchison J.G., IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies, Am. J. Gastroenterol., 2011, 106(1), 38–45 http://dx.doi.org/10.1038/ajg.2010.370Web of ScienceCrossrefGoogle Scholar

  • [28] Bedossa P., Poynard T., An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group, Hepatology, 1996, 24(2), 289–293 http://dx.doi.org/10.1002/hep.510240201CrossrefGoogle Scholar

  • [29] Backus L.I., Boothroyd D.B., Phillips B.R., Belperio P., Halloran J., Mole L.A., A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C, Clin. Gastroenterol. Hepatol., 2011, 9, 509–516 http://dx.doi.org/10.1016/j.cgh.2011.03.004CrossrefGoogle Scholar

  • [30] Brjalin V., Salupere R., Tallo T., Kuznetsova T., Priimägi L., Tefanova V., Efficacy of peginterferon alfa-2a and ribavirin combination therapy in treatment-naïve Estonian patients with chronic hepatitis C, Cent. Eur. J. Public Health, 2012, 20(2), 150–155 Google Scholar

  • [31] Lee S.S., Bain V.G., Peltekian K., Krajeden M., Yoshida E.M., Deschenes M., et al., Treating chronic hepatitis C with pegylated interferon alfa- 2a (40 KD) and ribavirin in clinical practice, Aliment. Pharmacol. Ther., 2006, 23, 397–408 http://dx.doi.org/10.1111/j.1365-2036.2006.02748.xCrossrefGoogle Scholar

  • [32] Mauss S., Hueppe D., John C., Goelz J., Heyne R., Moeller B., et al., Estimating the likelihood of sustained virological response in chronic hepatitis C therapy, J. Viral. Hepat., 2011, 18, 81–90 http://dx.doi.org/10.1111/j.1365-2893.2010.01372.xCrossrefGoogle Scholar

  • [33] Weich V., Herrmann E., Chung T.L., Sarrazin C., Hinrichsen H., Buggisch P., et al., The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection, J. Gastroenterol., 2011, 46(12), 1427–1436 http://dx.doi.org/10.1007/s00535-011-0458-yWeb of ScienceCrossrefGoogle Scholar

  • [34] Marcellin P., Cheinquer H., Curescu M., Dusheiko G.M., Ferenci P., Horban A., et al., High sustained virologic response rates in rapid virologic response patients in the large realworld PROPHESYS cohort confirm results from randomized clinical trials, Hepatology, 2012, 56(6), 2039–2050 http://dx.doi.org/10.1002/hep.25892CrossrefGoogle Scholar

  • [35] Navaneethan U., Kemmer N., Neff G.W., Predicting the probable outcome of treatment in HCV patients, Therap. Adv. Gastroenterol., 2009, 2(5), 287–302 http://dx.doi.org/10.1177/1756283X09339079CrossrefGoogle Scholar

  • [36] Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al., Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa- 2a plus ribavirin, Gastroenteroly, 2006, 130, 1086–1097 http://dx.doi.org/10.1053/j.gastro.2006.02.015Google Scholar

  • [37] Lindsay K.L., Morishima C., Wright E.C., Dienstag J.L., Shiffman M.L., Everson G.T., et al., Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C, Clin. Gastroenterol. Hepatol., 2008, 6(2), 234–241 http://dx.doi.org/10.1016/j.cgh.2007.11.020CrossrefWeb of ScienceGoogle Scholar

  • [38] Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., et al., Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection, N. Engl. J. Med., 1996, 334(2), 77–81 http://dx.doi.org/10.1056/NEJM199601113340203CrossrefGoogle Scholar

About the article

Published Online: 2013-12-06

Published in Print: 2013-12-01


Citation Information: Open Medicine, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-013-0221-2.

Export Citation

© 2013 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in